Evidence map›Paper›PMID 40803045›Full record

ArticleEmerging microbes & infections2025

Prior immunological memory to pertussis toxin affects the avidity development of anti-PT IgG antibodies after acellular pertussis booster vaccination.

Aapo Knuutila, Niina Ahvenainen, Alex-Mikael Barkoff, Jussi Mertsola, Pieter van Gageldonk, Annemarie Buisman, Marta Valente Pinto, Dominic Kelly, Qiushui He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aapo KnuutilaInstitute of Biomedicine, University of Turku, Turku, Finland.
Niina AhvenainenInstitute of Biomedicine, University of Turku, Turku, Finland.
Alex-Mikael BarkoffInstitute of Biomedicine, University of Turku, Turku, Finland.
Jussi MertsolaDepartment of Pediatric and Adolescent Medicine, Turku University Hospital, Turku, Finland.
Pieter van GageldonkNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, The Netherlands.
Annemarie BuismanNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, The Netherlands.
Marta Valente PintoDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Dominic KellyDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Qiushui HeInstitute of Biomedicine, University of Turku, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acellular pertussis vaccines are used in many countries. Since the quantity of antibodies after vaccination wanes quickly, to study functional antibody properties is important for evaluating long-lasting protection. Additionally, substantial variation in the quantity and quality of antibodies exists after vaccination in different age groups. The avidity of antibodies to pertussis toxin (PT) after Tdap3-IPV booster vaccination was studied in children, adolescents, young adults, and older adults. Serum samples (

Indexed as

Antibodies, BacterialAntibody AffinityDiphtheria-Tetanus-acellular Pertussis VaccinesImmunoglobulin GImmunologic MemoryPertussis ToxinWhooping CoughAdolescentAdultAgedChildChild, PreschoolFemaleFinlandHumansImmunization, SecondaryAntibodies, BacterialDiphtheria-Tetanus-acellular Pertussis VaccinesImmunoglobulin GPertussis ToxinPertussis VaccinePoliovirus Vaccine, InactivatedavidityELISAIgG antibodyPertussispertussis toxinvaccination

Identifiers

PMID40803045
PMCPMC12406325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.